• Our People
  • Global Presence
  • Regions
    • Asia
    • Europe
    • Americas
  • Offices
    • Canada
      • Ottawa
      • Toronto
    • China
      • Beijing
      • Hong Kong
    • France
      • Paris
      • Sophia Antipolis
    • Luxembourg
    • Malaysia
    • Singapore
    • UK
      • Aberdeen
      • Birmingham
      • Cambridge
      • Edinburgh
      • Glasgow
      • London
      • Manchester
      • Oxford
  • Client liaison
    • Japan
    • Korea
  • Expertise
  • Services
    • Patents
    • Brands & Trade Marks
    • Designs
    • Litigation & Dispute Resolution
    • Commercial IP & Contracts
    • Due Diligence
    • Freedom to Operate
    • EPO Patent Oppositions
    • European Patent Validations
    • Anti-counterfeiting
    • Open Source & Third Party Code
  • Sectors
    • Energy & Environment
    • Life Sciences
    • Agritech
    • Medical Technologies
    • Chemistry
    • Transport
    • Entertainment & Creative Industries
    • Food & Drink
    • Fashion & Retail
    • Universities & Research Bodies
    • Start-ups & Spin-outs
    • Digital Transformation
      • 3D Printing
      • Artificial Intelligence
      • Blockchain
      • Data & Connectivity
      • Extended Reality
      • Industry 4.0
  • About Us
    • Working with us
    • Awards
    • Corporate & Social Responsibility
    • Diversity & Inclusion
    • Careers
  • Insights
    • M&C Reacts
    • Beyond Brexit - UK & EU trade marks
    • Covid-19
    • Unitary Patent & Unified Patent Court
    • All publications
  • Contact Us
Marks & Clerk logo (magenta)
Marks & Clerk logo (magenta)
Contact Us
Language
English
Our People
Global Presence
Regions
  • Asia
  • Europe
  • Americas
Offices
  • Canada
    • Ottawa
    • Toronto
  • China
    • Beijing
    • Hong Kong
  • France
    • Paris
    • Sophia Antipolis
  • Luxembourg
  • Malaysia
  • Singapore
  • UK
    • Aberdeen
    • Birmingham
    • Cambridge
    • Edinburgh
    • Glasgow
    • London
    • Manchester
    • Oxford
Client liaison
  • Japan
  • Korea
Expertise
Services
  • Patents
  • Brands & Trade Marks
  • Designs
  • Litigation & Dispute Resolution
  • Commercial IP & Contracts
  • Due Diligence
  • Freedom to Operate
  • EPO Patent Oppositions
  • European Patent Validations
  • Anti-counterfeiting
  • Open Source & Third Party Code
Sectors
  • Energy & Environment
  • Life Sciences
  • Agritech
  • Medical Technologies
  • Chemistry
  • Transport
  • Entertainment & Creative Industries
  • Food & Drink
  • Fashion & Retail
  • Universities & Research Bodies
  • Start-ups & Spin-outs
  • Digital Transformation
    • 3D Printing
    • Artificial Intelligence
    • Blockchain
    • Data & Connectivity
    • Extended Reality
    • Industry 4.0
About Us
  • Working with us
  • Awards
  • Corporate & Social Responsibility
  • Diversity & Inclusion
  • Careers
Insights
  • M&C Reacts
  • Beyond Brexit - UK & EU trade marks
  • Covid-19
  • Unitary Patent & Unified Patent Court
  • All publications
Photo: Paul Chapman

Paul Chapman

Partner

Europe
Edinburgh

Get in contact

+44 131 221 7000 pchapman@marks-clerk.com
vCard

Paul is a Chartered (UK) and European Patent Attorney with over 25 years of experience in the IP profession. A number of his clients have worked with him since he started in the profession and still do so to this day. His clients range from universities and SMEs to large multinational companies particularly in the biotechnology, chemistry and pharmaceutical fields. His University clients currently include Birmingham, Edinburgh, Dundee, Durham, Strathclyde and St. Andrews.

He has significant expertise in biologics including, antibody technology, cell therapies, RNAi and vaccines. Paul also carries out a significant amount of work in relation to molecular and in vitro diagnostics, medical devices, anaerobic digestion, drug delivery, cancer therapeutics, catalysis, nanotechnology and DNA technologies. He has experience of European Opposition and Appeal procedures, in particular, in the areas of biotechnology, molecular biology and chemistry. Paul also has considerable experience of filing and prosecuting SPC applications throughout Europe. As well as prosecution and opposition work, Paul provides strategic advice to ensure that his clients get the best out of their IP.

Paul has authored and/or edited a number of the firm's life sciences reports and other publications and is a regular speaker at bioscience conferences and has given many presentations and workshops to universities and other clients.

Paul was recommended in 2016 by IAM Patent 1000, which says that “he constantly provides excellent service”. He was recommended in the 2015 edition of Legal 500, and mentioned in 2016. For the last two consecutive years, he has also been listed as ‘IP Star’ by Managing Intellectual Property.

Paul was brought up and educated in Edinburgh. He obtained an honours degree in microbiology from the University of Glasgow, followed by a doctorate in molecular biology.

Languages

  • English

Specialist in

  • Patents
  • Due Diligence
  • Chemistry
  • Life Sciences
  • Medical Technologies

Qualifications

Chartered (UK) and European Patent Attorney

PhD Molecular Biology, University of Glasgow

BSc Microbiology, University of Glasgow

Search our people

Latest Insights

Insight
- 07 April 2022

Has mass COVID diagnostic testing shifted our approach to diagnostic testing forever?

Despite improvements in the prognosis for patients infected with COVID-19 following the vaccination programme, the most recent statistics available at the time of writing (April 2022) suggest challenges in returning to ‘normal’ care remain.
Read more
Insight
- 02 March 2022

The Importance of Diagnostics

I would expect that practically everyone is now well aware of lateral flow tests and PCR, indeed many of us now have first-hand experience of these tests.
Read more
Insight
- 20 April 2020

The medical revolution of vaccination is something we take almost for granted

Early last month, reports said US-based Scottish scientist Dr Kate Broderick was actively developing a vaccine against Covid-19 and the speed of development was “unprecedented”.
Read more
Marks & Clerk logo (white)
  • Terms & Conditions
  • Privacy Notice
  • Cookies
  • Legal Notices
  • Lexology
  • Mondaq